Peptide Antibiotics Gain Momentum Amid Rising Resistance and R&D Advances
Peptide antibiotics appeal is increased by their capacity to target germs that are resistant to many drugs, as well as by developments in peptide synthesis and drug delivery technology. Other growth factors include increasing pharmaceutical R&D expenditures, growing awareness of hospital-acquired infections, and encouraging government programs for the development of novel antibiotics.
Key Growth Drivers and Opportunities
Rising Antibiotic Resistance: The increasing antibiotics resistance makes the conventional antibiotics less effective against bacteria that are resistant to multiple drugs leading towards adoption of peptide antibiotics. Novel peptide-based solutions have higher investments from government, healthcare institutions, and pharmaceutical corporations in order to counter the increasing global health danger posed by superbugs and the pressing need for new, effective therapies. With increasing demand for potent antimicrobials, the peptide antibiotics industry is seeing a surge in research, development, and commercialization.
Challenges
The peptide antibiotics mostly requires complicated and complex synthesis processes that can be expensive, consumes more time and labor-intensive as they need creating accurate sequences of amino acids with certain structures and clear modifications. To improve stability or activity of some procedures, solid-phase peptide synthesis, purification procedures, and chemical alterations are needed with each call for specific tools and knowledge. This intricacy increases production costs and restricts scalability.
Innovation and Expansion
New peptide antibiotic stops bacteria by binding where no drug has before
In March 2025, the lariocidin was discovered which is a lasso peptide making a breakthrough step ahead in antibiotics. Found by McMaster University researchers binds to a bacterial ribosome location which was previously untargeted, preventing protein production and leading to incorrect coding.
The antibiotics peptide effectively counters the multi-drug-resistant bacteria in animal models and lab studies, having a minimum toxicity and lower potential for resistance development.
New Human-Derived Peptides Show Promise Against Superbugs in June 2025 Breakthrough
In June 2025, a novel class of antimicrobial peptides (AMPs) have been identified by Researchers at Universitat Autònoma de Barcelona that is embedded within human glycosaminoglycan-binding proteins. In both in vitro experiments and mice sepsis models, HBP-5 showed strong, targeted efficacy against multidrug-resistant Gram-negative bacteria with no harm to human cells.
The Lariocidin's therapeutic potential in hostile biological conditions is further enhanced by its extraordinary durability against enzymatic degradation due to its unique lasso structure.
First Peptide-Based Long-Lasting Frown Line Treatment
In September 2022, The U.S. FDA has cleared DAXXIFY (DaxibotulinumtoxinA-lanm) for injection, according to a statement released by Revance Therapeutics. Since DAXXIFY is the first and only peptide-formulated neuromodulator that provides long-lasting cosmetic results, this is a significant milestone.
In comparison to current botulinum toxin treatments, the product is intended to lessen the appearance of frown lines and may have a longer duration of action.
Innovation in Antibiotics, Expand Markets
The key players operating in the peptide antibiotics market include, Merck & Co., Inc., Monarch Pharmachem, AbbVie Inc., VERRA, Melinta Therapeutics LLC, and others. Long-term goals consist of to improve product quality and scalability, peptide antibiotic firms are concentrating on innovation through robust research and development, strategic partnerships, and economical production.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.
TIME BUSINESS NEWS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
4 days ago
- Hamilton Spectator
This Hamilton-built AI could change how lung cancer is diagnosed in Canada
Lung cancer is not only the most commonly diagnosed cancer in Canada, it has an abysmally low survival rate of 25 per cent over a five-year period. Often, by the time it is correctly spotted, it is in an advanced stage and has spread to other parts of the body. A chief culprit for these bleak statistics is modern technology, which has surprisingly failed to advance lung cancer's timely detection. Now, however, NodeAI, a medical technology startup out of Hamilton, aims to upend this dismal trend with its novel, AI-powered diagnostic procedure that promises to save more lives with a startling 100 per cent increase in accuracy rates. Its new test will also pare sky-high diagnostic and treatment costs. 'It helps to decide if patients should go to the operating room or if they should go to the cancer centre and have chemotherapy,' explains NodeAI co-founder Dr. Waël Hanna, one of Canada's leading thoracic surgeons who practices at St. Joe's hospital in Hamilton, and is the brains behind NodeAI's solution. Hanna is also a pioneer in robotic surgery in the country and the head of the thoracic surgery division at McMaster University. Lung cancer diagnosis hinges on a crucial litmus test — determining if lymph nodes in the chest region are cancerous or not. 'Before you decide on treatment of lung cancer, whether it's surgery or chemotherapy or anything else, you have to evaluate the lymph nodes,' says Hanna. If they are found to be malignant, this often means that the cancer has spread to other parts of the body; in other words, escalated from stages 1, 2 or 3 to Stage 4. Dr. Waël Hanna, thoracic surgeon at St. Joe's Hospital and the brains behind his company's AI-powered solution that doubles the accuracy in detecting lung cancer A long-standing method of doing so is the endobronchial ultrasound-guided transbronchial needle aspiration — a mouthful, but commonly referred to as EBUS-TBNA. It involves sending a bronchoscope — a thin tube with a light and camera at the end — down the throat and into the chest in order to relay ultrasound images of the lymph nodes to an external screen. If the lymph nodes look compromised, a thin needle is then sent down the same path to extract a tissue sample, called a biopsy, in order to test for cancer. The problem is, the EBUS-TBNA procedure is both ancient and inaccurate. 'Ultrasound is very operator dependent, meaning that you and me can look at the same ultrasound image and only 20 per cent of the time will we agree on what it shows,' says Hanna. Which means, the decision to biopsy a lymph node — not an inexpensive process — is hit or miss. Errors result in unnecessary procedures, treatments and costs. Several years ago, Hanna was sitting contemplating this problem as well as the thousands of images of lymph nodes and associated lungs that he had instinctively squirrelled away over a decade of research and surgery. 'He had the foresight to keep these images as part of a research program because he thought, 'What else can be done with this?'' says Mackensey Bacon, co-founder and CEO of NodeAI, who is also a manager with the Research Institute of St. Joe's in Hamilton. Doing so is unusual. 'Say you have an ultrasound image for fetal monitoring when you have a baby, and they take a picture of that — it's stored as part of your medical record. But for lymph nodes, it's purely used as a guidance tool,' explains Bacon. 'It's not stored as part of the medical record.' That fateful day, when Hanna picked up his iPhone and unlocked it by looking at it, as most iPhone users tend to do, a light bulb went off. 'What if you could use this image-recognition technology to marry these records toward some kind of diagnostic tool?' he wondered. Hanna got in touch with Anthony Gatti, an expert in AI-driven medical imaging and currently a post-doctoral scholar in radiology at Stanford University and a co-founder of NodeAI, to engineer a solution. This ultimately involved training an algorithm on Hanna's treasure trove of images, and NodeAI's solution was born. Using deep neural network models and a data set of 2,569 images of lymph nodes, NodeAI's technology can now supercharge a EBUS-TBNA procedure. In under six seconds, it can compare a patient's lymph nodes to its own data set of cancerous lymph nodes and lungs in real time and deliver a reading with 85 per cent accuracy compared to 40 per cent previously. This vast improvement will save a considerable amount of time and money on costly — and often unnecessary — biopsies and flawed treatments plans. The innovation was good enough to win the $100,000 Ernsting Entrepreneurship prize in March — a highly competitive award given to one of six finalists in who are picked for their innovative technologies that detect or treat cancers. The award was part of Falcons' Fortunes pitch competition, currently in its 12th year, orchestrated by FACIT, a commercialization venture firm that helps accelerate oncology innovation in Ontario and has attracted more than $1.6 billion in investment to Ontario. 'I think we're all very passionate about improving care and cancer, which hits home to me,' says NodeAI CEO Bacon, whose father succumbed to chronic myeloid leukemia in Hamilton when she was four years old. 'It has been a motivator for me throughout my entire career,' she adds. The company is currently trialing its technology at the top cancer hospitals in Ontario, Alberta, Manitoba and Quebec, and is on its way to securing FDA and Health Canada approvals. 'Take all the cancers that you know of. Add them up together in terms of how many people they kill,' explains Hanna. 'All combined, they will kill less people than lung cancer every year.' NodeAI's AI-powered ultrasounds hopes to change that soon. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
Hamilton Spectator
5 days ago
- Hamilton Spectator
Future is Bright for Academic Partnership Program at Canada's National Nuclear Laboratory as Universities Agree to Five-Year Extensions
CHALK RIVER, Ontario, July 29, 2025 (GLOBE NEWSWIRE) — Canadian Nuclear Laboratories (CNL), Canada's premier nuclear science and technology laboratory, and Atomic Energy of Canada Limited (AECL), a federal Crown corporation with a mandate to drive nuclear opportunity for Canada, are pleased to announce that they have signed five-year extensions with all nine universities currently participating in CNL's Academic Partnership Program (APP). Developed to ensure Canada's R&D community is ready to fully support the country's ambitious climate change goals through nuclear energy – the APP is helping to establish a talent pipeline for the nuclear industry; encouraging collaborative research projects; and, facilitating joint access to the infrastructure, technology and expertise at Canada's national nuclear laboratories. Since it launched in 2022, the APP has grown rapidly, beginning with early participants that included McMaster University, the University of Ottawa and Ontario Tech University in 2022; Western University, the University of Waterloo, the University of New Brunswick and Queen's University, who joined in 2023; and, the University of Regina and the University of Saskatchewan, which saw the program expand west in 2024. These renewals extend the original agreements for an additional five-year period, positioning the Academic Partnership Program for continued growth and success. In its third year, the APP has engaged with over 7,000 students from across Canada. Among the many highlights is the launch of the Undergraduate Student Research Experience with McMaster University – a competitive, 16-week, experiential learning program designed to inspire and prepare future leaders in nuclear science and engineering. A similar program is also underway with Ontario Tech University, known as the Ontario Tech-CNL Graduate Immersive Experience Program. This week-long experience welcomes 15 graduate students to the Chalk River campus to learn about fusion technology, fusion fuel cycles and other fusion-related research, offering the opportunity to engage CNL leaders and tour facilities associated with this clean energy technology. These programs are in addition to the organization and delivery of numerous student engagement events and opportunities, including mentorship support, participation in guest lectures, student conferences and panel discussions, graduate and undergraduate research poster sessions, and capstone and design projects. CNL staff have directly participated in these engagements, sharing their knowledge and enthusiasm, making each event an enriching experience for students. 'On behalf of CNL, I want to express how excited and energized we are to extend these agreements with all of our university partners, and we look forward to sustaining the momentum we've built with the APP program over the next five years,' commented Dr. Stephen Bushby, Vice-President of Science and Technology at CNL. 'This program comes at a time when the nuclear industry is poised for significant growth, with small and large-scale nuclear reactors planned for construction here in Ontario, and other provinces moving closer towards nuclear deployment for the very first time. To make this clean energy future a reality, we need a new generation of nuclear engineers and technologies, and this program is intended to establish that talent pipeline.' 'AECL is proud to support the Academic Partnership Program, which plays a vital role in building Canada's nuclear future,' highlighted Karen Huynh, AECL's Director of Strategic Programs and Partnerships. 'By connecting students and researchers with our national nuclear laboratories, we are not only investing in the next generation of nuclear professionals, but also fostering the innovation needed to meet Canada's priorities in health, clean energy, safety and security and the environment. These renewed agreements reflect our shared commitment to collaboration, talent development, and scientific excellence. It presents an opportunity for us to work collaboratively in new initiatives such as the Canadian Nuclear Learning School to coordinate education, training, knowledge management and workforce development across Canada's growing nuclear sector.' For CNL, the APP has already strengthened its reputation as a hub for experiential learning, leading to a 90 per cent increase in co-op hires from universities participating in the program. Even more exciting, 40 per cent of CNL's new hires in the past fiscal year have come directly from APP partners, quickly demonstrating the effectiveness and value of the program as a talent pipeline. Collaborative research projects are also growing, with nine external funding proposals submitted this year, an increase of 125 per cent over the previous year, suggesting improved coordination in research proposal development as the APP continues to mature. 'In the first few years of this program, we've been able to implement a long list of meaningful and impactful engagements with students and future nuclear professionals, and we see lots of opportunities to grow the program in new ways,' added Dr. Gina Strati, Director of the Academic Partnership Program at CNL. 'In particular, we're looking forward to leveraging this university network to drive further innovation in nuclear R&D, with a focus on addressing the priorities of AECL's Federal Nuclear Science & Technology Work Plan.' Thanks to the support of AECL, CNL has just recently established new scholarship awards to support student education and development at partner universities. Through these agreements, CNL has committed a total of $260,000 in scholarship funding for science and engineering students, to be delivered over a three-to-five-year period. These scholarships not only directly invest in student success, but encourage interest in nuclear science, engineering, and other related disciplines. If you'd like to learn more about Canadian Nuclear Laboratories, including its Academic Partnership Program, please visit . About CNL As Canada's premier nuclear science and technology laboratory and working under the direction of Atomic Energy of Canada Limited (AECL), CNL is a world leader in the development of innovative nuclear science and technology products and services. Guided by an ambitious corporate strategy known as Vision 2030, CNL fulfills three strategic priorities of national importance – restoring and protecting the environment, advancing clean energy technologies, and contributing to the health of Canadians. By leveraging the assets owned by AECL, CNL also serves as the nexus between government, the nuclear industry, the broader private sector, and the academic community. CNL works in collaboration with these sectors to advance innovative Canadian products and services towards real-world use, including carbon-free energy, cancer treatments and other therapies, non-proliferation technologies and waste management solutions. To learn more about CNL, please visit . About Atomic Energy of Canada Limited Atomic Energy of Canada Limited (AECL) is a federal Crown corporation with a mandate to drive nuclear opportunities for Canada. Working through a government-owned / contractor-operated (GoCo) model that is executed by its contractor, Canadian Nuclear Laboratories, AECL enables nuclear science and technology through its Chalk River Laboratories, Canada's largest research complex, and by engaging with academia and private industry to advance nuclear innovation. It is committed to advancing reconciliation with Indigenous peoples. It also manages the Government of Canada's radioactive waste responsibilities. AECL continues to own the intellectual property for the CANDU® reactor technology and is accountable for deriving optimal benefit from this technology for Canada. Read more on AECL at . CNL Contact: Philip Kompass Director, Corporate Communications 1-866-886-2325 media@ A photo accompanying this announcement is available at:
Business Wire
5 days ago
- Business Wire
Centauri Therapeutics Receives an Additional $5.1M from CARB-X to Progress ABX-01 Lead Compound to First in Human Clinical Trials
ALDERLEY PARK, England--(BUSINESS WIRE)--Centauri Therapeutics Limited (' Centauri ' or 'the Company'), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, announced today that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an additional $5.1M in funding for the development of their lead compound. The funds will contribute to the advancement of the lead candidate in Centauri's ABX-01 programme into first in human clinical studies, and this latest funding brings CARB-X's total support from 2019 to date to $12.3M. Centauri announced the selection of its first clinical candidate in the ABX-01 programme in March 2025 1. The candidate is a broad-spectrum antimicrobial specifically selected to combat clinically prevalent and multidrug-resistant bacterial strains. Based on the Company's proprietary Alphamer ® platform, it is designed to target serious Gram-negative bacterial infections in the lung, expanding therapeutic options for the most vulnerable patients. It employs a dual mechanism of action, combining immunotherapeutic effects through complement fixation and phagocytosis with intrinsic antibacterial properties, within a single molecule. Early efficacy studies have demonstrated the compound's activity against Gram-negative bacteria. ' The unwavering scientific and financial support from CARB-X has provided stability to Centauri as a company, expanded understanding of our Alphamer platform, and enabled us to progress the ABX-01 programme from discovery, through early development, and is now providing a smooth and continuous path towards First in Human clinical studies, ' said Dr. Jennifer Schneider, Chief Executive Officer, Centauri Therapeutics. ' We are thankful for CARB-X and their continued engagement and confidence, which has allowed us to move a step closer to delivering a much needed therapeutic for serious, drug-resistant Gram-negative infections, even in the most clinically vulnerable patients. ' Dr. Erin Duffy, Chief of Research and Development, CARB-X, commented: 'We have been proud to support Centauri, beginning with answering key questions on the approach and continuing with the drug discovery that has led to the lead asset of ABX-01 and its progression towards building a dossier to support its advancement into first in human clinical trials. ' CARB-X's funding for this project is provided in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by awards from Wellcome (WT224842), and Germany's Federal Ministry of Research, Technology and Space (BMFTR). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders.
